News
News
- FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
02/28/2019 / 17:35 - GlobeNewswire - Roche enters into definitive merger agreement to acquire Spark Therapeutics
02/25/2019 / 07:00 - GlobeNewswire - FDA grants Priority Review to Roche's personalised medicine entrectinib
02/19/2019 / 07:03 - GlobeNewswire - FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma
02/19/2019 / 07:00 - GlobeNewswire - Roche joins the World Federation of Hemophilia Humanitarian Aid Program
02/06/2019 / 07:00 - GlobeNewswire - Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
02/05/2019 / 07:00 - GlobeNewswire - CHMP recommends EU approval of Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
02/01/2019 / 14:15 - GlobeNewswire - CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
02/01/2019 / 14:10 - GlobeNewswire - Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) - other company programmes in AD continue
01/30/2019 / 07:00 - GlobeNewswire - Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in urothelial cancer
01/24/2019 / 08:16 - GlobeNewswire
Real-time